Results 191 to 200 of about 3,014,693 (296)

One century of teaching, research, and innovation in chemical engineering in Mexico: The role of chemical engineering in the background and future of polymer science and industrial production in Mexico

The Canadian Journal of Chemical Engineering, EarlyView.
Timeline of key academic milestones and individuals that shaped chemical engineering at FQ‐UNAM and in Mexico. Abstract One hundred years after the beginning of the teaching of Chemical Engineering in Mexico, which started in 1925 in the former National School of Chemical Sciences, currently Faculty of Chemistry (FQ) at National Autonomous University ...
Patricia Pérez‐Salinas, Alberto Rosas‐Aburto, Eduardo Vivaldo‐Lima   +2 more
wiley   +1 more source

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies. [PDF]

J Cachexia Sarcopenia Muscle
Breen DM, Joaquim S, Paulhus BL, Bennett D, Bernardo B, Collins S, Esquejo RM, Kim-Muller JY, Lin L, Peloquin M, Wu Z, Qiao S, Stansfield JC, Zhang BB, Rossulek MI.   +14 more
europepmc   +1 more source

One hundred years of teaching, research, and innovation in chemical engineering at the Faculty of Chemistry, National Autonomous University of Mexico (UNAM): Birthplace and enduring leadership of the discipline in Mexico

The Canadian Journal of Chemical Engineering, EarlyView.
The teaching of chemical engineering in Mexico started in 1925 at the Faculty of Chemistry (FQ) of the National Autonomous University of Mexico (UNAM). Academic institutions, research centres, chemical companies, technological developments, highly trained personnel, and scientific contributions are part of the legacy from FQ‐UNAM.
Patricia Pérez‐Salinas, Alberto Rosas‐Aburto, Martín G. Hernández‐Luna, Aida Gutiérrez‐Alejandre, Eduardo Vivaldo‐Lima   +4 more
wiley   +1 more source

Unacylated ghrelin counteracts mitochondrial dysfunction and neuromuscular junction disruption in cancer cachexia. [PDF]

Am J Physiol Cell Physiol
Ahn B, Wanagat J, Cleary C, Ainsworth HC, Kim H.   +4 more
europepmc   +1 more source

Purification, Fluorescent Labeling, and Detyrosination of Mammalian Cell Tubulin for Biochemical Assays

Cytoskeleton, EarlyView.
ABSTRACT Microtubules play essential roles in numerous cellular processes. All microtubules are built from the protein tubulin, yet individual microtubules can differ spatially and temporally due to their tubulin isotype composition and post‐translational modifications (PTMs).
Ezekiel C. Thomas, Yang Yue, Morgan L. Pimm, Takashi Hotta, Ryoma Ohi, Kristen J. Verhey   +5 more
wiley   +1 more source

Early Identification and Prognostic Stratification of Cancer Cachexia Using Explainable Machine Learning: A Multicentre Cohort Study. [PDF]

J Cachexia Sarcopenia Muscle
Huang W, Pan K, Zhao M, Zhao T, Xu N, Shi H.   +5 more
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Educational program on cancer cachexia for nurses: a pilot randomized controlled trial. [PDF]

BMC Med Educ
Sato R, Hayashi N.
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design. [PDF]

Cancer Rep (Hoboken)
Othman NO, Habib H, Almeldin DM, Shohdy KS.   +3 more
europepmc   +1 more source